GENZYME CORPORATION for GENZYME CORPORATION

Taxation/Internal Revenue Code TAX

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE

Copyright/Patent/Trademark CPT

H.R. 1249/S. 23, the America Invents Act

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 1249 (112th), S. 23 (112th)

Health Issues HCR

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Drug Supply Chain Security AHRQ Report on Enzyme Replacement Therapy for Lysosomal Storage Diseases

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Deficit Reduction Proposals to Joint Committee Changes re: Medicare Part B and Average Sales Price H.R. 2672/S. 1423, Preserving Access to Orphan Drugs Act Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: S. 1423 (112th), H.R. 2672 (112th)

Budget/Appropriations BUD

FY 2012 Budget Appropriations H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 2112 (112th), H.J.Res. 94 (112th), H.R. 3765 (112th), H.J.Res. 95 (112th), H.R. 3671 (112th), H.R. 3743 (112th), H.R. 2055 (112th), H.R. 2608 (112th), H.R. 3630 (112th)

Pharmacy PHA

S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 2482, Drug Safety Enhancement Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 2245 (112th), H.R. 3059 (112th), S. 606 (112th), H.R. 2482 (112th), S. 296 (112th)